National Jewish Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Jewish Health sits in the top decile of US sponsors by registered trial count (#271 of 15,742 sponsors by registered trial count).
National Jewish Health: 83 sponsored US clinical trials, 7 recruiting.
National Jewish Health sponsors 83 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 60 completed. 5 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cystic Fibrosis, with 6 trials.
Top-decile sponsor footprint
National Jewish Health ranks in the top decile of sponsors by registered trial count (#271 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
60 of 65 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
83 total, page 1 of 2
Enhancing Hypnotic Medication Discontinuation in Primary Care
NCT06435520
Effect of Omalizumab in the Skin of Food Allergy Patients
NCT06618963
Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)
NCT06155747
Alveolar Macrophage Programming Following Endotoxin Exposure
NCT03859050
The Role of Laryngopharyngeal Reflux in IPF
NCT03418350
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
NCT02947945
Deployment-Related Lung Disease Research Database and Biorepository
NCT03035097
A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis
NCT04844359
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
NCT04598919
Host and Bacterial Mechanisms During Cystic Fibrosis Pulmonary Exacerbations
NCT04354038
Use of Blinded Tapering for Hypnotic Discontinuation
NCT04050176
Interactive Digital Technology to Assess and Improve Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus
NCT03746197
An Asthma Collaboration to Reduce Childhood Asthma Disparities on the Navajo Nation
NCT03377647
Utility of Lung Clearance Index Score As a Noninvasive Marker of Small Airways Disease
NCT03241420
Therapist-Directed VS Online Therapy for Insomnia Co-Occuring With Sleep Apnea
NCT03109210
Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
NCT03010436
MOBoxy: MoblO2 to Maintain Oxygenation
NCT07222592
Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma
NCT06270576
COVID-19 Vaccine Response in Chronic Respiratory Conditions
NCT05313087
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
NCT04283539
Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations
NCT04341532
Use of DNAse in Neutrophilic Asthma
NCT03994380
Skin Tape Transcriptome Methods in Children
NCT04180644
Observational Trial of the Longitudinal Effects of CFTR Modulator Drugs
NCT04353752
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
NCT04038710
Sildenafil Exercise: Role of PDE5 Inhibition
NCT04039087
Reverse HFpEF: Ketogenic Reversal of Heart Failure With Preserved Ejection Fraction Study
NCT04942548
Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in Cystic Fibrosis
NCT04024423
Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)
NCT02323100
Telehealth Cognitive Behavioral Stress Management for Adults With Cystic Fibrosis
NCT03560726
: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)
NCT03445793
Changing School Start Times: Impact on Student, Family, Teacher, and Community Health
NCT03964181
Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma
NCT02753764
The Breathe Well Program for Adults With Asthma
NCT02761837
IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy
NCT02918409
Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency
NCT02691611
Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
NCT02626182
The Role of Tapering Pace and Selected Traits on Hypnotic Discontinuation
NCT02831894
Effects of Sildenafil on CFTR-dependent Ion Transport Activity
NCT01132482
T Cell Memory Fuels the Innate Response in Chronic CF Lung Disease
NCT04397861
The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD)
NCT02596347
Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)
NCT02604693
Tailored Treatment to Enhance Risk Perception in Sleep Apnea
NCT02314858
Utility of CD64 and TLR2 Assays to Diagnose Acute Pulmonary Exacerbations in Cystic Fibrosis
NCT04397809
Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension
NCT02220634
Utility of Lung Clearance Index Score as a Noninvasive Marker of Deployment Lung Disease
NCT03012958
Correlation Between Trachebroncho Malacia/Hyperdynamic Airway Collapse And Obstructive Sleep Apnea
NCT02097212
COPDGene/Lung Cancer Center Database
NCT02445183
Supplemental Oxygen in Pulmonary Fibrosis
NCT01961362
FiteBac Hand Sanitizer in the Management of Hand Dermatitis in Adults
NCT01950494
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 8 |
| Phase 3 | 1 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the National Jewish Health pipeline
7 recruiting of 83 indexed (8% open); 60 completed (72%).
Phase mix: 5 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Cystic Fibrosis (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Jewish Health: open-pipeline peers nationwide
Peers matched on 83 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Jewish Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 83 trials (± recruiting share)
- Ferring Pharmaceuticals · 83 trials · 5% recruiting
- New York University · 83 trials · 30% recruiting
- Teva Pharmaceuticals USA · 83 trials · 0% recruiting
- Seagen · 84 trials · 0% recruiting
Sponsors near 8% open enrollment (± trial volume)
- National Institute of Neurological Disorders and Stroke (NINDS) · 8% recruiting · 567 trials
- Boehringer Ingelheim · 8% recruiting · 515 trials
- Acrotech Biopharma · 8% recruiting · 24 trials
- Atlanta VA Medical Center · 8% recruiting · 12 trials
Related
What to do with this National Jewish Health page
83 registered trials is a research-attention snapshot, not an endorsement of National Jewish Health or any single study.
- 7 of National Jewish Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cystic Fibrosis is the condition National Jewish Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cystic Fibrosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Jewish Health pipeline card: 83 registered trials from official public datasets.Report a data error.